FDA grants final approval to Bravnetsa for SSTR-positive GEP-NETs

The FDA has granted final approval to Lantheus' Bravnetsa for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.

Bravnetsa, or lutetium Lu 177 dotatate, has been determined by the FDA to be bioequivalent and therapeutically equivalent to Lutathera.

The approval adds another radioligand therapy option for SSTR-positive GEP-NETs and introduces further competition in the US nuclear-medicine market.

Field	Content
Alert Type	Approval
Drug Name	Lutetium Lu 177 dotatate
Brand Name	Bravnetsa
Company	Lantheus
Regulatory Authority	U.S. Food and Drug Administration
Approval Type	Final approval
Indication	Adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours
Therapy Area(s)	Oncology; neuroendocrine tumours
Technology or Modality	Radioligand therapy
Reference Product	Lutathera
Regulatory Status	FDA determined Bravnetsa to be bioequivalent and therapeutically equivalent to Lutathera
Geography	United States
What Happened	The FDA granted final approval to Bravnetsa for adults with SSTR-positive GEP-NETs.
Why It Matters	The approval introduces an additional therapeutically equivalent lutetium Lu 177 dotatate product and expands competition in radioligand treatment.
Supporting Context	Lutetium Lu 177 dotatate delivers targeted radiation to tumour cells expressing somatostatin receptors.
Key Takeaway	Bravnetsa is now fully FDA approved as a therapeutic equivalent to Lutathera for SSTR-positive GEP-NETs.
What to Watch	Commercial launch, treatment-centre adoption and the effect of additional competition on radioligand therapy access.
Primary Source	Lantheus
Relevant Date	22 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com